- Home
- NRK vs NBTX Comparison
NRK vs NBTX Comparison
Compare NRK & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRK
- NBTX
- Stock Information
- Founded
- NRK 2002
- NBTX 2003
- Country
- NRK United States
- NBTX France
- Employees
- NRK N/A
- NBTX N/A
- Industry
- NRK Trusts Except Educational Religious and Charitable
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- NRK Finance
- NBTX Health Care
- Exchange
- NRK Nasdaq
- NBTX Nasdaq
- Market Cap
- NRK 824.4M
- NBTX 868.8M
- IPO Year
- NRK N/A
- NBTX 2020
- Fundamental
- Price
- NRK $10.17
- NBTX $20.65
- Analyst Decision
- NRK
- NBTX Strong Buy
- Analyst Count
- NRK 0
- NBTX 1
- Target Price
- NRK N/A
- NBTX $8.00
- AVG Volume (30 Days)
- NRK 187.3K
- NBTX 118.1K
- Earning Date
- NRK 01-01-0001
- NBTX 09-30-2025
- Dividend Yield
- NRK 4.10%
- NBTX N/A
- EPS Growth
- NRK N/A
- NBTX N/A
- EPS
- NRK N/A
- NBTX N/A
- Revenue
- NRK N/A
- NBTX $11,930,711.00
- Revenue This Year
- NRK N/A
- NBTX N/A
- Revenue Next Year
- NRK N/A
- NBTX $74.67
- P/E Ratio
- NRK N/A
- NBTX N/A
- Revenue Growth
- NRK N/A
- NBTX N/A
- 52 Week Low
- NRK $8.95
- NBTX $2.76
- 52 Week High
- NRK $11.09
- NBTX $22.85
- Technical
- Relative Strength Index (RSI)
- NRK 67.20
- NBTX 72.61
- Support Level
- NRK $10.06
- NBTX $19.11
- Resistance Level
- NRK $10.29
- NBTX $22.64
- Average True Range (ATR)
- NRK 0.08
- NBTX 1.64
- MACD
- NRK -0.00
- NBTX 0.64
- Stochastic Oscillator
- NRK 54.84
- NBTX 84.58
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.